SUBSCRIBE
SUBSCRIBE

DiaMedica Therapeutics, Inc.

NEWS
Drug Development
DiaMedica Ischemic Stroke Program Remains on Hold with Plans for Additional Studies
Minneapolis-based DiaMedica Therapeutics plans to conduct additional studies in order to resolve a clinical hold on its DM199 program for the treatment of acute ischemic stroke (AIS).
October 27, 2022
 · 
2 min read
 · 
Mark Terry
Pictured: Stop sign in front of FDA headquarters/S
Drug Development
DiaMedica Ischemic Stroke Program Hits Another Bump in the Road
DiaMedica Therapeutics’ Phase II/III ReMEDy2 trial is on hold by the FDA because patients were experiencing severe drops in blood pressure.
July 7, 2022
 · 
3 min read
 · 
Hannah Chudleigh
Business
BioSpace Movers & Shakers, Feb. 4
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.
February 3, 2022
 · 
9 min read
 · 
Alex Keown
Deals
Updated: BioSpace’s List of December 2018 Life Sciences IPOs
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
December 21, 2018
 · 
1 min read
 · 
Editorial Staff
Job Trends
Struggling DiaMedica Inc. Cuts Jobs; CFO Out
December 10, 2014
 · 
1 min read
JOBS
IN THE PRESS
Press Releases
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
November 14, 2024
 · 
7 min read
Press Releases
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
November 14, 2024
 · 
19 min read
Press Releases
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
November 13, 2024
 · 
1 min read
Press Releases
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
November 6, 2024
 · 
1 min read
Press Releases
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
October 9, 2024
 · 
8 min read
Press Releases
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
July 11, 2024
 · 
10 min read
BioMidwest
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
July 1, 2024
 · 
9 min read
BioMidwest
DiaMedica Therapeutics Announces $11.8 Million Private Placement
June 26, 2024
 · 
8 min read
BioMidwest
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
June 26, 2024
 · 
13 min read
Business
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
May 8, 2024
 · 
14 min read
Load More